Cybin Inc (CYBN) Stock Price, Quote & News

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology

Sector: Healthcare

Website: cybin.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

Mastacash Jan. 2 at 4:49 PM

$CYBN interesting price action..don’t you think??this sector and particularly this stock could be the ultimate idiosyncratic play. The anxiety and mdd market is up for major disruption, these therapies work, it’s just a matter of time before the data proves it. Even if they only pick up a few billion in revenue the company is currently at 400mil market cap, major upside potential. And you could consider this sector recession proof, in fact a recession would boost revenue as depression would increase.

1 · Reply

DJTHollaAtMe Jan. 2 at 3:43 PM

$AUPH $WEN $CYBN $FLG No brainers in 2026. Load the boats boys and girls!!!!

0 · Reply

Mastacash Jan. 2 at 3:08 PM

$CYBN above all major moving averages for the first time in years, just bounced off the short term 8dma, if that support holds its very bullish for medium term. Unless the sector takes a huge setback via regulation or trial results, the bear story for $CYBN is over imo.

0 · Reply

DJTHollaAtMe Jan. 2 at 2:31 PM

$CYBN $22+ in 2026

0 · Reply

ChristopherMcC Jan. 2 at 1:21 PM

$CYBN why do an atm, when you could issue long-term high interest paper that you can buy back at a significant premium the next month, and THEN pop off an ATM.

1 · Reply

Cybaghold Jan. 1 at 9:25 PM

$CYBN

1 · Reply

Printingmoney247 Jan. 1 at 7:08 AM

$CYBN Happy New Year!!

0 · Reply

Irichdialed Jan. 1 at 5:17 AM

$CYBN seems they will sell runs here and there with the new atm. I just take that as the stock price won't get too high until they get through the 100 million.... and honestly until they get something to market.

1 · Reply

Mastacash Jan. 1 at 1:18 AM

$CYBN after the initial low volume drop the buyers came in all day, qqq red and this stock hung in like a champ. Just remember, when the catalysts line up and the market is a believer, raising capital becomes a catalyst as well, watch closely the new 13f filings in the new year. Positioning will be telling on where this is going.

0 · Reply

Michael_MDC Dec. 31 at 9:35 PM

$CYBN as long as no daily closes under $7.95 it looks bullish . Worst case $7.46 .. but we hold above that it looks decent , need to get a nice close over the massive volume bar . Target 🎯 11$

1 · Reply

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 18, 2025, 12:29 PM EST - 15 days ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Nov 13, 2025, 3:11 PM EST - 7 weeks ago

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 7:20 AM EST - 7 weeks ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:30 AM EST - 7 weeks ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:30 AM EST - 2 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 7:30 AM EST - 2 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 2 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 2 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 2 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 3 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 11, 2025, 3:59 PM EDT - 4 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 7:30 AM EDT - 4 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 4, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 4 months ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 4 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 13, 2025, 5:30 PM EDT - 5 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 7, 2025, 7:30 AM EDT - 5 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 17, 2025, 7:30 AM EDT - 6 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 6 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 10:03 PM EDT - 6 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 9:27 PM EDT - 6 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 13, 2025, 7:45 AM EDT - 7 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 12, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 11, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 3, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

May 22, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 20, 2025, 7:30 AM EDT - 8 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 15, 2025, 7:30 AM EDT - 8 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 14, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 8, 2025, 7:30 AM EDT - 8 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 1, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Apr 23, 2025, 7:30 AM EDT - 9 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 21, 2025, 8:00 AM EDT - 9 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Feb 10, 2025, 9:48 PM EST - 11 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Jan 15, 2025, 12:07 PM EST - 1 year ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 13, 2025, 7:30 AM EST - 1 year ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 9, 2025, 5:00 PM EST - 1 year ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 10, 2024, 7:30 AM EST - 1 year ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 4, 2024, 7:30 AM EST - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Nov 18, 2024, 7:00 AM EST - 1 year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 14, 2024, 7:30 AM EST - 1 year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Mastacash Jan. 2 at 4:49 PM

1 · Reply

DJTHollaAtMe Jan. 2 at 3:43 PM

$AUPH $WEN $CYBN $FLG No brainers in 2026. Load the boats boys and girls!!!!

0 · Reply

Mastacash Jan. 2 at 3:08 PM

0 · Reply

DJTHollaAtMe Jan. 2 at 2:31 PM

$CYBN $22+ in 2026

0 · Reply

ChristopherMcC Jan. 2 at 1:21 PM

$CYBN why do an atm, when you could issue long-term high interest paper that you can buy back at a significant premium the next month, and THEN pop off an ATM.

1 · Reply

Cybaghold Jan. 1 at 9:25 PM

$CYBN

1 · Reply

Printingmoney247 Jan. 1 at 7:08 AM

$CYBN Happy New Year!!

0 · Reply

Irichdialed Jan. 1 at 5:17 AM

1 · Reply

Mastacash Jan. 1 at 1:18 AM

0 · Reply

Michael_MDC Dec. 31 at 9:35 PM

$CYBN as long as no daily closes under $7.95 it looks bullish . Worst case $7.46 .. but we hold above that it looks decent , need to get a nice close over the massive volume bar . Target 🎯 11$

1 · Reply

JohnTrack Dec. 31 at 8:40 PM

$CYBN Material Change Report https://www.rapidticker.com/news/cybn-sec-filing-be7841

0 · Reply

firetypecracker Dec. 31 at 7:44 PM

$CYBN

0 · Reply

garygb Dec. 31 at 6:46 PM

$CYBN They can't keep this one down.

1 · Reply

cambruck7 Dec. 31 at 6:11 PM

$CYBN here come all the same old dumbass bears who were saying it would be 4 before the end of the year

1 · Reply

Bbbb44444 Dec. 31 at 5:56 PM

$CYBN How low do we go?

0 · Reply

mcgr Dec. 31 at 5:36 PM

$CYBN to those new here, welcome back to the reality of a dilution machine

0 · Reply

Rico_Again_Jorge Dec. 31 at 5:06 PM

$CYBN HEAL US 🤡

3 · Reply

kev90123 Dec. 31 at 5:01 PM

$CYBN

0 · Reply

Rico_Again_Jorge Dec. 31 at 4:45 PM

$CYBN This “pumped” gap will disappear sooner or later

0 · Reply

ZRadly Dec. 31 at 4:24 PM

$CYBN Space SiDU🤑

0 · Reply

prismmarketview Dec. 31 at 2:54 PM

Cybin (NYSE: $CYBN) has set up a new at‑the‑market equity program that lets it sell up to 100 million U.S. dollars of common shares over time through Cantor Fitzgerald, with proceeds earmarked for growth initiatives and working capital and no obligation to issue any stock unless management chooses. https://prismmarketview.com/cybin-establishes-up-to-100-million-at-the-market-equity-program/

0 · Reply

AStrokeOfLuck Dec. 31 at 2:51 PM

$CYBN

0 · Reply

Market Cap	206.04M
Revenue (ttm)	0.00
Net Income (ttm)	-81.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	458,164
Avg Vol	934,620
Day's Range	N/A - N/A
Shares Out	25.19M
Stochastic %K	61%
Beta	0.67
Analysts	Strong Sell
Price Target	$45.00